PMA device
Integra Dermal Regeneration Template
Integra Lifesciences Corp. · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision Sep 8, 2017, newest Sep 8, 2017BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
4
Naming "Dermal Regeneration Template"
MAUDE reports
0
Brand "Dermal Regeneration Template", since 2015
PubMed studies
300
Mentioning "Dermal Regeneration Template"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Integra Dermal Regeneration Template
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Dermal Regeneration Template", any status and sponsor, newest update first.
- A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem CellsNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT05344521 · 29 participants (planned) · Start Feb 2024 · Primary completion Feb 2026
Device: Integra®; Integra®-SC · For: Burns
Sites: Hamilton, Canada
- Direct Application of Integra Bilayer Matrices on Bare Calvarium Without Preliminary BurringStatus unknown
Joshua ChooAcademic, hospital or other
NCT05311124 · 10 participants (planned) · Start Aug 1, 2022 · Primary completion Jun 1, 2023
Device: Integra Dermal Regeneration template (IDRT) · For: Wound Care; Pressure Ulcer; Venous Ulcer and 3 more
Sites: Louisville, Kentucky
- Bacterial Load for Integra™ in Operative WoundsStatus unknown
Georgetown UniversityAcademic, hospital or other
NCT04543240 · 54 participants (planned) · Start Dec 14, 2017 · Primary completion Jan 1, 2021
Device: Integra™ dermal regeneration template · For: Wounds and Injuries
Sites: Washington D.C., District of Columbia
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dermal Regeneration Template", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MGR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Dermal Regeneration Template"[tiab]. The summary above synthesizes these.
- Dermal Regeneration Template: Reconstruction in Oral Cancer Defects.
Mangini N, Galvano F, Pucci R, et al. · J Maxillofac Oral Surg · 2023
- Integra® Dermal Regeneration Template: From Design to Clinical Use.
Taupin P, Gandhi A, Saini S · Cureus · 2023Review
- An ADSC-loaded dermal regeneration template promotes full-thickness wound healing.
Xu J, Chen X, Wang J, et al. · Regen Ther · 2024
- Integra Dermal Regeneration Template in reconstructive surgery for cutaneous tumours: a two-year retrospective review.
Prezzavento GE, Calvi RNJ, Rodriguez JA, et al. · J Wound Care · 2022
- Integra® Dermal Regeneration Template in Complex Scalp Reconstruction.
Turton N, Aggarwal A, Twohig E, et al. · J Clin Med · 2024
- Axillary hidradenitis reconstruction using a dermal regeneration template.
Kraft C, Pearson G · Wounds · 2022
- Innovative Indigenous Cost-effective Bilaminar Dermal Regeneration Template.
Shijina K, Chittoria RK, Chavan V, et al. · J Cutan Aesthet Surg · 2021
- Meshed dermal regeneration template for traumatic periocular tissue loss in the young population.
Avila SA, Wojno T, de la Garza AG, et al. · Orbit · 2024Case Reports
- Use of Integra dermal regeneration template in burn patients: An Italian expert consensus Delphi study.
Giudice G, Ranno R, Lombardo G, et al. · Burns · 2024Consensus Statement
- Histologic Features of Dermal Regeneration Template Identified in Mohs Layer Frozen Sections.
McGuinness AE, Richey PM, Stone MS, et al. · Dermatol Surg · 2022
- Nasal Reconstruction Using the Integra Dermal Regeneration Template.
Seth AK, Ratanshi I, Dayan JH, et al. · Plast Reconstr Surg · 2019
- The Basics of Integra Dermal Regeneration Template and its Expanding Clinical Applications.
Chang DK, Louis MR, Gimenez A, et al. · Semin Plast Surg · 2019Review
Other devices of this type
Also filed under product code MGR.
- ApligrafOrganogenesis, Inc. · PMA 2013
- TranscyteShire Regenerative Medicine · PMA 2004
- DermagraftShire Regenerative Medicine · PMA 2012
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Apilgraf(Graftskin)Organogenesis, Inc. · PMA 2002
- Orcel Bilayered Cellular MatrixForticell Bioscience · PMA 2001
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.